# Apremilast for RAS

> **NCT03690544** · PHASE4 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 15 (actual)

## Conditions studied

- Recurrent Aphthous Stomatitis

## Interventions

- **DRUG:** Apremilast 30mg

## Key facts

- **NCT ID:** NCT03690544
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-12
- **Primary completion:** 2021-07-14
- **Final completion:** 2021-07-14
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03690544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03690544, "Apremilast for RAS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03690544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*